Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO...

Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008
ASCO Annual Meeting
Two oral presentations, two poster discussion presentations, three poster
presentations

SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL) announced today that data from clinical trials of the
company's investigational compounds XL647, XL184, XL765 and XL880 will be
presented at the 2008 American Society of Clinical Oncology (ASCO) Annual
Meeting, which will be held from May 30 to June 3, 2008 in Chicago, Illinois.
The clinical trial data will be described in two oral presentations (XL184 and
XL765), two poster presentations and discussions (XL647), and three poster
presentations (XL647 and XL880).
Oral Presentations
-- XL184 (RET, MET, VEGFR2). Data from a phase 1 trial of XL184 in
patients with advanced malignancies, including medullary thyroid
cancer, will be presented on Sunday, June 1, 2008, starting at 10 a.m.
local time (Abstract #3522).
-- XL765 (PI3K, mTOR). Data from a phase 1 trial of XL765 in patients
with advanced solid tumors will be presented on Saturday, May 31,
2008, starting at 1:15 p.m. local time (Abstract #3510).

Poster Presentations and Discussions
-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in
NSCLC patients with acquired resistance to EGFR tyrosine kinase
inhibitors will be presented on Monday, June 2, 2008, during the 8
a.m.-noon session (Abstract #8028).
-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 1 trial of XL647 dosed
daily in patients with advanced solid malignancies will be presented
on Saturday, May 31, 2008, during the 8 a.m.-noon session (Abstract
#3528).

Poster Presentations
-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in
clinically selected NSCLC patients enriched for the presence of EGFR
mutations will be presented on Sunday, June 1, 2008, during the 2-6
p.m. session (Abstract #8053).
-- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in patients
with papillary renal cell carcinoma will be presented on Saturday, May
31, 2008, during the 8 a.m.-noon session (Abstract #5103).
-- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in MET
amplified, poorly differentiated gastric cancer will be presented on
Monday, June 2, 2008, during the 8 a.m.-2 p.m. session (Abstract
#4572).

* XL880 was selected by GlaxoSmithKline in December 2007 for further
development and commercialization.

About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for the
treatment of cancer and other serious diseases. The company is leveraging its
fully integrated drug discovery platform to fuel the growth of its development
pipeline, which is primarily focused on cancer. Currently, Exelixis' broad
product pipeline includes investigational compounds in phase 2 and phase 1
clinical development. Exelixis has established strategic corporate alliances
with major pharmaceutical and biotechnology companies, including
GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth
Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the
company's web site at http://www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
SOURCE Exelixis, Inc.

Charles Butler, Senior Director, Corporate Communications & Investor
Relations, +1-650-837-7277, cbutler@exelixis.com, or Soleil Harrison, Senior
Manager, Corporate Communications, +1-650-837-7012, sharriso@exelixis.com,
both of Exelixis, Inc.